Skip to main content
. 2024 Sep 5;25(10):6503–6514. doi: 10.1021/acs.biomac.4c00672

Figure 1.

Figure 1

Effects of ABT-737 and Purvalanol A treatments on pediatric acute myeloid leukemia cell lines as separate and combined treatments. (A) MV4-11, MOLM-13, and MOLM-14 cells were treated for 72 h with 50 nM ABT-737 or 1.3 μM Purvalanol A, as single or mixed drug treatments, prior to assessment of cell viability by CellTiter-Glo. (B) Combination index (CI) values obtained after a 72 h drug cotreatment for each fraction of cells affected by the combination (Fa). CI values were calculated following CellTiter-Glo assay, using the Chou–Talalay method on CompuSyn software, where CI = 1 indicates an additive combination, CI > 1 an antagonistic effect, and CI < 1 a synergistic effect. Figure keys denote ABT-737/Purvalanol A molar ratios. (C) MV4-11, MOLM-13, and MOLM-14 cells were treated for 72 h with 50 nM ABT-737 or 1.3 μM Purvalanol A, as single or mixed drug treatments, prior to assessment of caspase 3/7 activity by Caspase 3/7 Glo. (D) Cell cycle analysis in MV4-11 cells using RNase/PI staining and flow cytometry upon 24 h of treatment with a range of concentrations of free ABT-737 or Purvalanol A. Data are presented as mean ± SD, n = 3.